

Axel Schlitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4289945/publications.pdf>

Version: 2024-02-01

44
papers

1,707
citations

411340
20
h-index

312153
41
g-index

44
all docs

44
docs citations

44
times ranked

2982
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison between bicycle ergometric interval and continuous training in patients early after coronary artery bypass grafting: A prospective, randomized study. SAGE Open Medicine, 2021, 9, 205031212110382.	0.7	2
2	Cardiac Rehabilitation in German Speaking Countries of Europe – Evidence-Based Guidelines from Germany, Austria and Switzerland LLKardReha-DACH – Part 1. Journal of Clinical Medicine, 2021, 10, 2192.	1.0	23
3	Polymorphism of CD14 Gene Is Associated with Adverse Outcome among Patients Suffering from Cardiovascular Disease. Mediators of Inflammation, 2021, 2021, 1-10.	1.4	1
4	Periodontal pathogens and their role in cardiovascular outcome. Journal of Clinical Periodontology, 2020, 47, 173-181.	2.3	16
5	ANRIL polymorphisms (rs1333049 and rs3217992) in relation to plasma CRP levels among in-patients with CHD. Cytokine, 2020, 127, 154932.	1.4	8
6	Interactive patient education via an audience response system in cardiac rehabilitation. SAGE Open Medicine, 2020, 8, 205031212094211.	0.7	3
7	Subgroups of monocytes predict cardiovascular events in patients with coronary heart disease. The PHAMOS trial (Prospective Halle Monocytes Study). Hellenic Journal of Cardiology, 2019, 60, 311-321.	0.4	24
8	Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry. International Journal of Cardiology, 2018, 253, 35-39.	0.8	7
9	Prognosis of patients with pulmonary embolism after rehabilitation. Vascular Health and Risk Management, 2018, Volume 14, 183-187.	1.0	23
10	Letter to the Editor regarding Dounousi E et al. Intact FGF23 and Klotho during acute inflammation/sepsis in CKD patients. European Journal of Clinical Investigation, 2017, 47, 468-469.	1.7	2
11	Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis, 2017, 266, 234-239.	0.4	31
12	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. European Heart Journal, 2017, 38, 2671-2679.	1.0	243
13	Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clinical Cardiology, 2017, 40, 1264-1270.	0.7	2
14	The interleukin 6 c.-174 CC genotype is a predictor for new cardiovascular events in patients with coronary heart disease within three years follow-up. Cytokine, 2016, 83, 136-138.	1.4	6
15	Data on IL-6 c.-174 G>C genotype and allele frequencies in patients with coronary heart disease in dependence of cardiovascular outcome. Data in Brief, 2016, 8, 1295-1299.	0.5	1
16	Periodontal conditions and incidence of new cardiovascular events among patients with coronary vascular disease. Journal of Clinical Periodontology, 2016, 43, 918-925.	2.3	26
17	C-reactive protein levels and genetic variants of CRP as prognostic markers for combined cardiovascular endpoint (cardiovascular death, death from stroke, myocardial infarction, and) Tj ETQq1 1 0.784314.rgBT /Overlock 10	1.0	1
18	Rehabilitation in Patients With Coronary Heart Disease. Deutsches Ärztblatt International, 2015, 112, 527-34.	0.6	13

#	ARTICLE	IF	CITATIONS
19	Feasibility and safety of rehabilitation after venous thromboembolism. <i>Vascular Health and Risk Management</i> , 2015, 11, 397.	1.0	25
20	Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. <i>PLoS ONE</i> , 2015, 10, e0128492.	1.1	8
21	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: The AFCAS study. <i>International Journal of Cardiology</i> , 2015, 183, 105-110.	0.8	17
22	Cardiotoxicity and Oncological Treatments. <i>Deutsches A&#x0308;rztblatt International</i> , 2014, 111, 161-8.	0.6	73
23	Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>BMJ Open</i> , 2014, 4, e004700.	0.8	15
24	Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1995-2001.	0.7	26
25	CHADS ₂ , CHA ₂ DS ₂ -VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2014, 133, 560-566.	0.8	58
26	Bivalirudin use during percutaneous coronary intervention in patients on chronic warfarin therapy. <i>Thrombosis Research</i> , 2014, 133, 695-696.	0.8	8
27	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E864-70.	0.7	19
28	Serum Phospholipid Transfer Protein Activity After a High Fat Meal in Patients with Insulin-Treated Type 2 Diabetes. <i>Lipids</i> , 2010, 45, 129-135.	0.7	3
29	Monocyte heterogeneity in obesity and subclinical atherosclerosis. <i>European Heart Journal</i> , 2010, 31, 369-376.	1.0	172
30	Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. <i>Thrombosis and Haemostasis</i> , 2009, 101, 1163-1169.	1.8	13
31	PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. <i>Journal of Lipid Research</i> , 2009, 50, 723-729.	2.0	35
32	In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. <i>Coronary Artery Disease</i> , 2008, 19, 279-284.	0.3	12
33	Phospholipid Transfer Protein in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2007, 27, 138-143.	1.4	11
34	Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. <i>Coronary Artery Disease</i> , 2007, 18, 523-531.	0.3	53
35	Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. <i>Nutrition and Metabolism</i> , 2006, 3, 5.	1.3	108
36	Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. <i>Journal of Heart Valve Disease</i> , 2006, 15, 809-14.	0.5	11

#	ARTICLE	IF	CITATIONS
37	Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles. <i>Journal of Lipid Research</i> , 2005, 46, 196-200.	2.0	24
38	Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2005, 102, 477-485.	0.8	25
39	Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005, 1733, 187-191.	1.2	49
40	Herpesvirus DNA (Epstein-Barr virus, herpes simplex virus, cytomegalovirus) in circulating monocytes of patients with coronary artery disease. <i>Acta Cardiologica</i> , 2005, 60, 605-610.	0.3	18
41	CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF- $\hat{\pm}$ levels. <i>Thrombosis and Haemostasis</i> , 2004, 92, 419-424.	1.8	276
42	Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). <i>Thrombosis Research</i> , 2003, 109, 131-135.	0.8	49
43	High Plasma Phospholipid Transfer Protein Levels as a Risk Factor for Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1857-1862.	1.1	120
44	Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. <i>Thrombosis and Haemostasis</i> , 2003, 90, 245-251.	1.8	17